Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.

As of March 31, 2009, Optimer held cash, cash equivalents and short-term investments of $62.6 million.

"We are off to a strong start in 2009," said Michael N. Chang, Ph.D., Optimer's President and CEO. "We announced plans to prepare a marketing application in Europe based on the results of the first fidaxomicin Phase 3 trial for Clostridium difficile infection. We also reported positive top-line results from the second prulifloxacin Phase 3 trial for the treatment of infectious diarrhea."

Recent Corporate Highlights

  • Announced plans to prepare a Marketing Authorization Application (MAA) for submission with the European Medicines Agency (EMEA) for approval of fidaxomicin as an oral treatment for Clostridium difficile infection (CDI) based on the results from the Company's first Phase 3 fidaxomicin trial.
  • Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
  • Announced positive results from the second pivotal Phase 3 trial of prulifloxacin for the treatment of infectious diarrhea. The trial achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). Median TLUS for patients treated with prulifloxacin was 32.8 hours which was statistically significant compared to the TLUS for placebo with a p-value of less than 0.0001. Prulifloxacin was generally well tolerated and had a similar safety profile compared to placebo. This is the second of two pivotal Phase 3 clinical studies which will be used to support an NDA submission with the U.S. Food and Drug Administration.
  • Raised $32.9 million in gross proceeds through the sale of 3.3 million shares and warrants to purchase 91,533 shares in a registered direct offering in March 2009.
  • Appointed Francois-Xavier Frapaise, M.D., as Senior Vice President and Chief Scientific Officer and Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations at Cephalon, Inc. (Nasdaq: CEPH), to the company's Board of Directors.
  • Published in vitro data highlighting the antibacterial activity of prulifloxacin in the peer-reviewed journal Antimicrobial Agents and Chemotherapy.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and prulifloxacin, the timing of clinical trials and anticipated results, and plans related to regulatory filings, including a potential MAA for fidaxomicin. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval, the timing of regulatory submissions and the uncertainty regarding whether such submissions will be accepted or approved, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

                        Optimer Pharmaceuticals, Inc.
                    Consolidated Statements of Operations

                                                  Three Months Ended March 31,
                                                         2009         2008
                                                         ----         ----

      Research grants                                  $83,012    $486,666
    Operating expenses:
      Research and development                       8,798,582   6,905,376
      Marketing                                        310,286     365,568
      General and administrative                     2,048,500   1,737,051
                                                     ---------   ---------
        Total operating expenses                    11,157,368   9,007,995
                                                    ----------   ---------
    Loss from operations                           (11,074,356) (8,521,329)
    Interest income and other, net                     186,968     581,284
                                                       -------     -------
    Net loss                                       (10,887,388) (7,940,045)
                                                   ===========  ==========

    Basic and diluted net loss per share                $(0.36)     $(0.28)
                                                        ======      ======

    Shares used to compute basic and diluted net
     loss per share                                 30,535,577  27,869,675
                                                    ==========  ==========

                         Optimer Pharmaceuticals, Inc.
                     Condensed Consolidated Balance Sheets

                                                    March 31,   December 31,
                                                      2009         2008
                                                      ----         ----
    Current assets:
        Cash and cash equivalents                 $46,788,899  $16,778,880
        Short-term investments                     15,794,624   22,547,515
        Prepaid expenses and other current assets     682,419      744,670
                                                      -------      -------
    Total current assets                           63,265,942   40,071,065
    Restricted cash                                   170,000      170,000
    Property and equipment, net                       667,100      694,183
    Long-term investments                             982,000    1,032,000
    Other assets                                      327,197      328,250
                                                      -------      -------
    Total assets                                  $65,412,239  $42,295,498
                                                  ===========  ===========

    Current liabilities:
        Accounts payable                           $4,049,160   $3,767,831
        Accrued expenses                            4,152,398    4,045,660
                                                    ---------    ---------
    Total current liabilities                       8,201,558    7,813,491
    Deferred rent                                     268,166      251,504
    Commitments and contingencies                           -            -
    Stockholders' equity                           56,942,515   34,230,503
                                                   ----------   ----------
    Total liabilities and stockholders' equity    $65,412,239  $42,295,498
                                                  ===========  ===========


    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):